Steroid Receptor Coactivator-2 as a key hepatic tumor suppressor and circadian me

类固醇受体辅激活因子-2 作为关键的肝肿瘤抑制因子和昼夜节律

基本信息

  • 批准号:
    8526200
  • 负责人:
  • 金额:
    $ 3.94万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-07-24 至 2015-07-23
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Hepatocellular carcinoma (HCC) is the most common and highly lethal form of liver cancer, yet the molecular mechanisms underlying HCC pathogenesis remain poorly understood. Interestingly, disruption of metabolic regulation is frequently observed in HCC patients, suggesting that it may play a causative role in HCC initiation and/or progression. Metabolic regulation principally relies on transcriptional control ad our lab has discovered that Steroid Receptor Coactivator (SRC) family members are major regulators of metabolic gene transcription. In particular, SRC-2 deletion perturbs liver metabolic function through aberrant regulation of gluconeogenesis and bile acid export. My preliminary data suggests that SRC-2 acts as a hepatic tumor suppressor with loss of SRC-2 increasing liver carcinogenesis following diethylnitrosamine (DEN) injection as compared to SRC-2+/+ controls. Recently, we also found that SRC-2 deficiency significantly disrupts the central and peripheral circadian clocks causing abnormal cycling of known circadian and diurnal metabolic genes. Additionally, SRC- 2 can co-activate the primary circadian heterodimeric transcription factor complex Bmal1: clock; and preliminary analysis of liver SRC-2 ChIP-Seq data reveals that SRC-2 and Bmal1 share many targets including those involved in hepatic metabolism and stress response pathways. Previous publications indicate that loss of critical circadian genes including Bmal1, Per1/2, and Cry1/2 results in inapt energy regulation and spontaneous liver tumorigenesis. This proposal aims to better understand the overarching effects of SRC-2 as a tumor suppressor. I plan to investigate the molecular impact of SRC-2 ablation on the circadian clock in Specific Aim 1 by comparing RNA and protein expression of key circadian and circadian controlled metabolic and stress response genes from liver tissue in entrained SRC-2+/+ and SRC-2-/- animals. Additionally, I will investigate possible differences in plasma glucose, bile acid, triglyceride, and hepatic stress markers in entrained SRC- 2+/+ and SRC-2-/- animals. We plan to further investigate the potential interactions of SRC-2 with circadian transcription factor via co-immunoprecipitation and chromatin immunoprecipitation assays. Specific Aim 2 will investigate the effect of chronic circadian disruption on hepatic stress and tumorigenesis in SRC-2+/+ and SRC-2-/- animals measuring tumor incidence, performing histology for stress markers, and measuring plasma markers of hepatic stress. With the increasing prevalence of HCC, it is imperative that we understand the molecular mechanisms linking circadian rhythms with carcinogenesis. As a well-established energy coregulator, SRC-2 may serve as a primary regulator of the circadian clock and a hepatic tumor suppressor synchronizing hepatic metabolism with the central clock. Therefore, I hypothesize that SRC-2 is an essential hepatic tumor suppressor necessary for regulation of circadian transcription factors to maintain metabolic synchrony in the liver and expect that loss of SRC-2 disrupts the circadian clock causing aberrant metabolic signaling, leading to hepatic stress and eventual hepatocellular carcinoma.
描述(由申请人提供):肝细胞癌(HCC)是最常见和高致死性的肝癌形式,但HCC发病机制的分子机制仍然知之甚少。有趣的是,在HCC患者中经常观察到代谢调节的破坏,这表明它可能在HCC的发生和/或进展中起致病作用。代谢调控主要依赖于转录调控,本实验室发现类固醇受体辅激活因子(SRC)家族成员是代谢基因转录的主要调控因子。特别地,SRC-2缺失通过异常调节肝脏生成和胆汁酸输出来扰乱肝脏代谢功能。我的初步数据表明,SRC-2作为一种肝肿瘤抑制剂,与SRC-2+/+对照相比,SRC-2的缺失增加了二乙基亚硝胺(DEN)注射后的肝癌发生。最近,我们还发现SRC-2缺乏显著地破坏了中枢和外周生物钟,导致已知的昼夜节律和昼夜代谢基因的异常循环。此外,SRC- 2可以共激活主要的昼夜异二聚体转录因子复合物Bmal 1:clock;对肝脏SRC-2 ChIP-Seq数据的初步分析表明,SRC-2和Bmal 1共享许多靶标,包括参与肝脏代谢和应激反应途径的靶标。先前的出版物表明,包括Bmal 1、Per 1/2和Cry 1/2在内的关键昼夜节律基因的缺失导致能量调节不适当和自发性肝肿瘤发生。该提案旨在更好地了解SRC-2作为肿瘤抑制剂的总体作用。我计划通过比较携带SRC-2+/+和SRC-2-/-动物肝组织中关键昼夜节律和昼夜节律控制的代谢和应激反应基因的RNA和蛋白质表达,研究SRC-2消融对Specific Aim 1生物钟的分子影响。此外,我将研究携带SRC- 2+/+和SRC-2-/-动物中血糖、胆汁酸、甘油三酯和肝应激标志物的可能差异。我们计划通过免疫共沉淀和染色质免疫沉淀分析进一步研究SRC-2与昼夜节律转录因子的潜在相互作用。具体目标2将研究慢性昼夜节律破坏对SRC-2+/+和SRC-2-/-动物的肝脏应激和肿瘤发生的影响,测量肿瘤发生率,对应激标志物进行组织学检查,并测量肝脏应激的血浆标志物。随着肝癌发病率的增加,我们必须了解昼夜节律与癌发生之间的分子机制。SRC-2作为一种能量辅助调节因子,可能是生物钟的主要调节因子,也可能是肝脏肿瘤抑制因子,使肝脏代谢与中枢生物钟同步。因此,我假设SRC-2是调节昼夜节律转录因子以维持肝脏中代谢同步所必需的重要肝脏肿瘤抑制因子,并预期SRC-2的缺失破坏昼夜节律钟,引起异常代谢信号传导,导致肝脏应激和最终肝细胞癌。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ERIN STASHI其他文献

ERIN STASHI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ERIN STASHI', 18)}}的其他基金

Steroid Receptor Coactivator-2 as a key hepatic tumor suppressor and circadian me
类固醇受体辅激活因子-2 作为关键的肝肿瘤抑制因子和昼夜节律
  • 批准号:
    8392567
  • 财政年份:
    2012
  • 资助金额:
    $ 3.94万
  • 项目类别:
Steroid Receptor Coactivator-2 as a key hepatic tumor suppressor and circadian me
类固醇受体辅激活因子-2 作为关键的肝肿瘤抑制因子和昼夜节律
  • 批准号:
    8688178
  • 财政年份:
    2012
  • 资助金额:
    $ 3.94万
  • 项目类别:
Steroid Receptor Coactivator-2 as a key hepatic tumor suppressor and circadian me
类固醇受体辅激活因子-2 作为关键的肝肿瘤抑制因子和昼夜节律
  • 批准号:
    8602865
  • 财政年份:
    2012
  • 资助金额:
    $ 3.94万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 3.94万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 3.94万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 3.94万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 3.94万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 3.94万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 3.94万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 3.94万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 3.94万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 3.94万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 3.94万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了